Company intelligence / Profile preview

ChemGenex Pharmaceuticals

Ownership: Private
Development stage: Phase 2

Overview

ChemGenex developed targeted oncology drugs, most notably omacetaxine mepesuccinate ("Omapro") for drug-resistant CML. The company's pivotal trial faced regulatory challenges regarding diagnostic testing and efficacy data. Its lead asset's US launch was delayed due to FDA concerns about trial design and patient selection. European rights to Omapro were licensed out in a deal worth up to $136 million. All major development programs have since been discontinued or are pending with no recent activity reported.

Therapeutic areas: Oncology
Modalities: Small moleculesTargeted therapies
Industry: Biotech

Drug pipeline

2 assets

homoharringtonine

Phase 2/3

Indications: Chronic Myelogenous Leukemia, Myelodysplastic Syndrome

1 more asset in the full pipeline.

Request access →

Partnerships

Licensed European/Middle East/Africa rights for Omapro in a deal worth up to $136 million as of late December prior to acquisition.

Beyond the preview

Go deeper on ChemGenex Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChemGenex Pharmaceuticals.

Explore the full profile